ClinicalTrials.gov
ClinicalTrials.gov Menu

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03713320
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : December 11, 2018
Sponsor:
Information provided by (Responsible Party):
miRagen Therapeutics, Inc.

Brief Summary:

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype. Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The study will compare the effects of cobomarsen to vorinostat, a drug that has been approved for the treatment of CTCL in the United States, Canada, and Australia.

Participants will be randomly assigned to receive either weekly doses of cobomarsen or daily doses of vorinostat. Participants will continue on their assigned treatment as long as their disease does not get worse or as long as they do not have unacceptable side effects. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects.

Participants assigned to receive vorinostat who experience progression of their disease during their participation in this study may have the option to be treated with cobomarsen in a separate clinical trial, if they meet the entry criteria for that study.


Condition or disease Intervention/treatment Phase
Cutaneous T-Cell Lymphoma/Mycosis Fungoides Drug: Cobomarsen Drug: Vorinostat Phase 2

Detailed Description:

Study Design:

Subjects will be randomly assigned in a 1:1 ratio to receive either cobomarsen or vorinostat. A total of 126 subjects (63 per arm) will be enrolled. Cobomarsen will be administered in the clinic by intravenous infusion on Days 1, 3, 5 and 8, and weekly thereafter. Vorinostat will be dispensed to study subjects and taken as a daily oral dose according to the manufacturer's labeled dosing instructions. Treatment will continue until the subject becomes intolerant, develops clinically significant side effects, progresses, or the trial is terminated.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Actual Study Start Date : September 12, 2018
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : September 2021


Arm Intervention/treatment
Experimental: Cobomarsen
At least weekly doses of cobomarsen throughout study treatment period
Drug: Cobomarsen
Intravenous infusion
Other Name: MRG-106

Active Comparator: Vorinostat
Daily doses of vorinostat throughout study treatment period
Drug: Vorinostat
Oral capsules




Primary Outcome Measures :
  1. Proportion of subjects achieving an objective response of at least 4 months duration (ORR4) [ Time Frame: Up to 36 months ]
    Based on composite global response criteria including radiological imaging, flow cytometry, and the modified Severity Weighted Assessment Tool (mSWAT).


Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: From date of randomization until the date of progression or death from any cause, up to a maximum of 36 months ]
  2. Pruritus Numerical Rating Scale [ Time Frame: Daily, up to a maximum of 36 months ]
    Measures the patient's degree of itch related to mycosis fungoides based on an 11-point scale (from 0-10), with 0 being no itch and 10 being worst imaginable itch.

  3. Skindex-29 Dermatological Survey [ Time Frame: Monthly, up to a maximum of 36 months ]
    Measures the effects of skin disease on quality of life based on a 30-item questionnaire. The patient's responses are transformed to a linear scale from 0 to 100 and averaged to determine a subscore in three domains (Symptoms, Emotions and Functioning), as well as a total score. Lower scores indicate a lesser degree of skin disease interference with quality of life.

  4. Pain Numerical Rating Scale [ Time Frame: Daily, up to a maximum of 36 months ]
    Measures the patient's intensity of pain related to mycosis fungoides based on an 11-point scale (from 0-10), with 0 being no pain and 10 being worst imaginable pain.

  5. Duration of composite global response for responding subjects [ Time Frame: Up to 36 months ]
  6. Complete response rate [ Time Frame: Up to 36 months ]
    Based on composite global response criteria including radiological imaging, flow cytometry, and mSWAT.

  7. Skin disease severity based on modified Severity-weighted Assessment Tool (mSWAT) [ Time Frame: Monthly, up to a maximum of 36 months ]
    Measures skin disease severity based on the percentage of skin within each body region with patches, plaques, or tumors. Total scores are calculated by adding the total percent for each category of lesion (patch, plaque, or tumor) and multiplying by a weighting factor. Weighted subtotals are added together to obtain the total score. Lower scores indicate a lower degree of skin disease severity.

  8. Time to progression [ Time Frame: From date of randomization until the date of progression, up to a maximum of 36 months ]
  9. Overall survival [ Time Frame: From date of randomization until the date of death from any cause, up to a maximum of 36 months ]
  10. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to 36 months ]
  11. Plasma concentration of cobomarsen [ Time Frame: From Day 1 to End of Treatment visit, up to a maximum of 36 months ]
    Sparse pharmacokinetic samples will be collected for the purpose of population PK model development and analysis of covariate effects.


Other Outcome Measures:
  1. Number of participants with anti-drug antibody generation [ Time Frame: Up to 36 months ]
  2. Change from baseline in Mycosis Fungoides/Sézary Syndrome Cutaneous T-cell Lymphoma-Quality of Life (MF/SS CTCL QOL) instrument [ Time Frame: Up to 36 months ]
    Measures the impact of CTCL on patients' quality of life based on a 12-item questionnaire. The patient's total scaled score is determined from the sum of the 12 item scores and may range from 62 to 154. Lower scores indicate a lesser degree of CTCL disease interference with quality of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Biopsy-proven CTCL, MF subtype
  • Clinical stage IB, II, or III, with staging based on screening assessments
  • Minimum mSWAT score of 10 at screening
  • Receipt of at least one prior therapy for CTCL

Key Exclusion Criteria:

  • Previous enrollment in a cobomarsen study
  • Prior therapy with vorinostat or other HDAC inhibitors, or contraindication to an HDAC inhibitor
  • Sézary syndrome or mycosis fungoides with B2 involvement, defined as documented history of B2 and/or B2 staging at screening
  • B1 blood involvement at screening
  • Lymph node involvement at screening, unless radiologically or histologically confirmed to be nonmalignant
  • Visceral involvement related to MF at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03713320


Locations
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
Contact: Rosemarie Abary    626-218-8087    rabary@coh.org   
Principal Investigator: Christiane Querfeld, MD         
Chao Family Comprehensive Cancer Center at University of California, Irvine Recruiting
Orange, California, United States, 92868
Contact: Blake Johnson    714-456-3476    Blakej@uci.edu   
Principal Investigator: Lauren Pinter-Brown, MD         
United States, Connecticut
Smilow Cancer Hospital at Yale-New Haven Not yet recruiting
New Haven, Connecticut, United States, 06510
Principal Investigator: Francine Foss, MD         
United States, Florida
Moffitt Cancer Center Not yet recruiting
Tampa, Florida, United States, 33612
Principal Investigator: Lubomir Sokol, MD, PhD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63108
Contact: Mary Tabacchi, CCRC    314-362-8171    mtabacch@wustl.edu   
Principal Investigator: Amy Musiek, MD         
United States, New York
Rochester Skin Lymphoma Medical Group Not yet recruiting
Fairport, New York, United States, 14450
Principal Investigator: Brian Poligone, MD, PhD         
United States, Ohio
The Ohio State University Comprehensive Cancer Center Not yet recruiting
Columbus, Ohio, United States, 43210
Principal Investigator: Basem William, MD         
Canada, Alberta
Cross Cancer Institute Not yet recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Principal Investigator: Minakshi Taparia, MD         
Canada, Ontario
Princess Margaret Cancer Centre Not yet recruiting
Toronto, Ontario, Canada, M5G 2C1
Principal Investigator: Vishal Kukreti, MD         
Canada, Quebec
Jewish General Hospital Not yet recruiting
Montréal, Quebec, Canada, H3T 1E2
Principal Investigator: Kevin Pehr, MD         
Sponsors and Collaborators
miRagen Therapeutics, Inc.
Investigators
Study Director: Diana Escolar, MD miRagen Therapeutics, Inc.

Responsible Party: miRagen Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03713320     History of Changes
Other Study ID Numbers: MRG106-11-201
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: December 11, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by miRagen Therapeutics, Inc.:
SOLAR
Cutaneous T-cell Lymphoma
CTCL
Mycosis Fungoides
Lymphoma
Lymphoma, T-cell
Lymphoma, T-cell, cutaneous
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms
MicroRNAs
Vorinostat
Histone Deacetylase Inhibitors

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Mycoses
Mycosis Fungoides
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Vorinostat
Histone Deacetylase Inhibitors
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action